Skip to main content
Erschienen in: Pediatric Cardiology 8/2012

01.12.2012 | Original Article

Increased α1-Antitrypsin Levels in Acute-Phase Kawasaki Disease as Shown by SELDI-TOF MS Analysis

verfasst von: Takahiro Kanai, Hirohiko Shiraishi, Ritei Uehara, Takane Ito, Mariko Y. Momoi

Erschienen in: Pediatric Cardiology | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Various agents have been suggested as causal or associated factors in the pathogenesis of Kawasaki disease (KD); however, the underlying factors of KD remain unknown. Plasma exchange is one of the most effective treatments for the acute phase of KD. This indicates that plasma may contain factors associated with the pathogenesis of KD. To search for proteins that may be involved in KD pathogenesis, we analyzed serum proteins with surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS). Serum samples were obtained from 17 KD patients. Serum from six of the patients was collected during acute phase before acetylsalicylic acid (ASA) and intravenous immunoglobulin administration (phase A1), during remission with ASA (phase A2), and during remission without any medication (phase A3). Serum from the remaining 11 patients was collected for phases A1 and A2 only. There were two age- and sex-matched control groups comprising 8 afebrile healthy children (group B) and 8 febrile children with several infectious diseases (group C). There were no statistical differences in laboratory examination between phase A1 and group C except for albumin level, alanine aminotransferase, or sodium level. Serum samples were analyzed by SELDI-TOF MS after purification. We detected five peaks, i.e., those were specifically increased or decreased during phase A1, and identified 1 of these as α1-antitrypsin (α1-AT). α1-AT can inhibit neutrophil elastase activity. This elastase is thought to play a role in coronary artery damage. Our findings present an interesting starting point for further investigations into the pathophysiology of KD.
Literatur
1.
Zurück zum Zitat Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M (2005) Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 174:5837–5845PubMed Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M (2005) Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 174:5837–5845PubMed
2.
Zurück zum Zitat Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867CrossRefPubMed Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867CrossRefPubMed
3.
Zurück zum Zitat Brantly M (2002) Alpha1-antitrypsin: not just an antiprotease: extending the half-life of a natural anti-inflammatory molecule by conjugation with polyethylene glycol. Am J Respir Cell Mol Biol 27:652–654PubMed Brantly M (2002) Alpha1-antitrypsin: not just an antiprotease: extending the half-life of a natural anti-inflammatory molecule by conjugation with polyethylene glycol. Am J Respir Cell Mol Biol 27:652–654PubMed
4.
Zurück zum Zitat Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33:805–810CrossRefPubMed Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33:805–810CrossRefPubMed
5.
Zurück zum Zitat Iino M, Shiraishi H, Igarashi H, Honma Y, Momoi MY (2003) Case of Kawasaki disease in NICU. Pediatr Int 45:580–583CrossRefPubMed Iino M, Shiraishi H, Igarashi H, Honma Y, Momoi MY (2003) Case of Kawasaki disease in NICU. Pediatr Int 45:580–583CrossRefPubMed
6.
Zurück zum Zitat Inamo Y, Harada K, Okuni M, Kimoto K, Takeuchi S, Sakurabayashi I (1987) Immunoreactive polymorphonuclear leukocyte elastase in complex with alpha 1-antitrypsin in Kawasaki disease. Acta Paediatr Jpn 29:202–205CrossRefPubMed Inamo Y, Harada K, Okuni M, Kimoto K, Takeuchi S, Sakurabayashi I (1987) Immunoreactive polymorphonuclear leukocyte elastase in complex with alpha 1-antitrypsin in Kawasaki disease. Acta Paediatr Jpn 29:202–205CrossRefPubMed
7.
Zurück zum Zitat Issaq HJ, Veenstra TD, Conrads TP, Felschow D (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292:587–592CrossRefPubMed Issaq HJ, Veenstra TD, Conrads TP, Felschow D (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292:587–592CrossRefPubMed
8.
Zurück zum Zitat Khurana M, Traum AZ, Aivado M, Wells MP, Guerrero M, Grall F et al (2006) Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr Nephrol 21:1257–1265CrossRefPubMed Khurana M, Traum AZ, Aivado M, Wells MP, Guerrero M, Grall F et al (2006) Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr Nephrol 21:1257–1265CrossRefPubMed
9.
Zurück zum Zitat Popper SJ, Shimizu C, Shike H, Kanegaye JT, Newburger JW, Sundel RP et al (2007) Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol 8:R261CrossRefPubMed Popper SJ, Shimizu C, Shike H, Kanegaye JT, Newburger JW, Sundel RP et al (2007) Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol 8:R261CrossRefPubMed
10.
Zurück zum Zitat Rieger CH, Kawasaki T, Yanase Y, Pollack U (1983) Complement and protease inhibitors in the mucocutaneous lymph node syndrome. Eur J Pediatr 140:92–97CrossRefPubMed Rieger CH, Kawasaki T, Yanase Y, Pollack U (1983) Complement and protease inhibitors in the mucocutaneous lymph node syndrome. Eur J Pediatr 140:92–97CrossRefPubMed
11.
Zurück zum Zitat Rocken C, Ebert MP, Roessner A (2004) Proteomics in pathology, research and practice. Pathol Res Pract 200:69–82CrossRefPubMed Rocken C, Ebert MP, Roessner A (2004) Proteomics in pathology, research and practice. Pathol Res Pract 200:69–82CrossRefPubMed
12.
Zurück zum Zitat Shiraishi H, Iino M, Hoshina M, Ichihashi K, Momoi MY (2007) Intravenous immunoglobulin 1 g/kg as the initial treatment for Kawasaki disease. World J Pediatr 6:195–199 Shiraishi H, Iino M, Hoshina M, Ichihashi K, Momoi MY (2007) Intravenous immunoglobulin 1 g/kg as the initial treatment for Kawasaki disease. World J Pediatr 6:195–199
13.
Zurück zum Zitat Sundel RP (2002) Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 4:474–482CrossRefPubMed Sundel RP (2002) Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 4:474–482CrossRefPubMed
14.
Zurück zum Zitat Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y (2005) Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 47:305–310CrossRefPubMed Takahashi K, Oharaseki T, Naoe S, Wakayama M, Yokouchi Y (2005) Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 47:305–310CrossRefPubMed
15.
Zurück zum Zitat Takahashi K, Oharaseki T, Yokouchi Y (2011) Pathogenesis of Kawasaki disease. Clin Exp Immunol 164(Suppl 1):20–22CrossRefPubMed Takahashi K, Oharaseki T, Yokouchi Y (2011) Pathogenesis of Kawasaki disease. Clin Exp Immunol 164(Suppl 1):20–22CrossRefPubMed
16.
Zurück zum Zitat Takeshita S, Nakatani K, Kawase H, Seki S, Yamamoto M, Sekine I et al (1999) The role of bacterial lipopolysaccharide-bound neutrophils in the pathogenesis of Kawasaki disease. J Infect Dis 179:508–512CrossRefPubMed Takeshita S, Nakatani K, Kawase H, Seki S, Yamamoto M, Sekine I et al (1999) The role of bacterial lipopolysaccharide-bound neutrophils in the pathogenesis of Kawasaki disease. J Infect Dis 179:508–512CrossRefPubMed
17.
Zurück zum Zitat Weinberger SR, Dalmasso EA, Fung ET (2002) Current achievements using ProteinChip array technology. Curr Opin Chem Biol 6:86–91CrossRefPubMed Weinberger SR, Dalmasso EA, Fung ET (2002) Current achievements using ProteinChip array technology. Curr Opin Chem Biol 6:86–91CrossRefPubMed
18.
Zurück zum Zitat Wilson KA, Lindholt JS, Hoskins PR, Heickendorff L, Vammen S, Bradbury AW (2001) The relationship between abdominal aortic aneurysm distensibility and serum markers of elastin and collagen metabolism. Eur J Vasc Endovasc Surg 21:175–178CrossRefPubMed Wilson KA, Lindholt JS, Hoskins PR, Heickendorff L, Vammen S, Bradbury AW (2001) The relationship between abdominal aortic aneurysm distensibility and serum markers of elastin and collagen metabolism. Eur J Vasc Endovasc Surg 21:175–178CrossRefPubMed
19.
Zurück zum Zitat Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H et al (2000) Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 181:1101–1109CrossRefPubMed Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H et al (2000) Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 181:1101–1109CrossRefPubMed
Metadaten
Titel
Increased α1-Antitrypsin Levels in Acute-Phase Kawasaki Disease as Shown by SELDI-TOF MS Analysis
verfasst von
Takahiro Kanai
Hirohiko Shiraishi
Ritei Uehara
Takane Ito
Mariko Y. Momoi
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 8/2012
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-012-0329-1

Weitere Artikel der Ausgabe 8/2012

Pediatric Cardiology 8/2012 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.